SCHEMBL2428337

SCHEMBL2428337

CCCCCc1c(C=O)ccc(OC)c1F

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALOX5 P09917 6/20 0.39
SLC2A1 P11166 1/20 0.38
PTGS2 P35354 1/20 0.37
ERN1 O75460 2/20 0.36
PPARA Q07869 2/20 0.36
PPARG P37231 1/20 0.36
SLC16A3 O15427 1/20 0.36
SLC16A1 P53985 1/20 0.36
GPR55 Q9Y2T6 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TSHR P16473 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2432372 0.95 ALDH1A1 (0.43) ALDH1A1L3MBTL1ALOX5SLC2A1ERN1
SCHEMBL2433196 0.89 ALDH1A1 (0.45) ALDH1A1L3MBTL1ERN1KDM4ETSHR
SCHEMBL2432111 0.83 ALDH1A1 (0.47) ALDH1A1L3MBTL1ERN1KDM4ETSHR
SCHEMBL5111354 0.82 ALOX5 (0.52) ALDH1A1L3MBTL1ALOX5PTGS2ERN1
SCHEMBL2432260 0.81 KDM4E (0.43) ALDH1A1PPARAPPARGSLC16A3SLC16A1
SCHEMBL2432259 0.81 KDM4E (0.43) ALDH1A1PPARAPPARGSLC16A3SLC16A1
SCHEMBL2431682 0.79 PDE4D (0.39) ALDH1A1L3MBTL1ALOX5ERN1KDM4E
SCHEMBL12035700 0.79 FDPS (0.46) ALDH1A1KDM4E
SCHEMBL9810574 0.77 HIF1A (0.49) ALDH1A1PTGS2KDM4ETSHR
SCHEMBL28104171 0.77 ALOX5 (0.42) ALDH1A1ALOX5SLC2A1PTGS2PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582674-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF CYMABAY THERAPEUTICS INC (US) 2014-10-01 EP disclosed
EP-2582674-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF CYMABAY THERAPEUTICS INC (US) 2014-10-01 EP disclosed
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2014-05-01 US disclosed
US-8598374-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-12-03 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-20130131351-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2013-05-23 US disclosed
US-20130131351-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2013-05-23 US disclosed
US-20130131351-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2013-05-23 US disclosed
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2011-12-22 US disclosed
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2011-12-22 US disclosed
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2011-12-22 US disclosed
WO-2011159297-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-22 WO disclosed
EP-2367793-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-09-28 EP disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR ALDH1A1 3347/4885L3MBTL1 3731/4885ALOX5 2053/4885
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR ALDH1A1 3347/4885L3MBTL1 3731/4885ALOX5 2053/4885
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR ALDH1A1 3347/4885L3MBTL1 3731/4885ALOX5 2053/4885
US-20130131351-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR ALDH1A1 3347/4885L3MBTL1 3731/4885ALOX5 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.